Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 15/20 | 0.72 |
| ▸ | INSR | P06213 | 14/20 | 0.72 |
| ▸ | IGF1R | P08069 | 14/20 | 0.72 |
| ▸ | EGFR | P00533 | 6/20 | 0.72 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.64 |
| ▸ | AURKA | O14965 | 1/20 | 0.64 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.64 |
| ▸ | JAK2 | O60674 | 1/20 | 0.64 |
| ▸ | STK10 | O94804 | 1/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.64 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.64 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | CD74 | P04233 | 1/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.64 |
| ▸ | LCK | P06239 | 1/20 | 0.64 |
| ▸ | FYN | P06241 | 1/20 | 0.64 |
| ▸ | FES | P07332 | 1/20 | 0.64 |
| ▸ | CSF1R | P07333 | 1/20 | 0.64 |
| ▸ | YES1 | P07947 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12728597 | 0.92 | INSR (0.69) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL12728598 | 0.92 | PLK1 (0.64) | ALKINSRIGF1REGFRPLK1 | |
| SCHEMBL12728730 | 0.91 | INSR (0.59) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL12728593 | 0.90 | ALK (0.68) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL26611568 | 0.90 | EGFR (0.74) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL12728589 | 0.90 | INSR (0.71) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL26612137 | 0.85 | ALK (0.72) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL12780998 | 0.85 | EGFR (0.77) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL11916520 | 0.85 | INSR (0.98) | ALKINSRIGF1REGFRCHEK1 | |
| SCHEMBL26612055 | 0.84 | EGFR (0.75) | ALKINSRIGF1REGFRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098280-A1 | 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS | TYMS, TYMP, DPYD | ALK 3384/4885INSR 3201/4885IGF1R 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.